Control of colon cancer development and progression by selected estrogen receptor modulators

References

• Mandalà M, Mosconi S, Quadri A et al. Neoadjuvant chemotherapy for patients with liver metastasis from colorectal cancer. Expert Rev. Anticancer. Ther.7(6), 887–897 (2007).
   PubMed Web of Science ®Google Scholar
• Bishop JM. Molecular themes in oncogenesis. Cell64(2), 235–248 (1991).
   PubMed Web of Science ®Google Scholar
• Ponder BA. Molecular genetics of cancer. BMJ304(6836), 1234–1236 (1992).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal tumor development. N. Engl. J. Med.319(9), 525–532 (1988).
   PubMed Web of Science ®Google Scholar
• Fearon ER, Cho KR, Nigro JM et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science247(4938), 49–56 (1990).
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature386(6627), 761–763 (1997).
   PubMed Web of Science ®Google Scholar
• Bodmer WF, Bailey CJ, Bodmer J et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature328(6131), 614–616 (1987).
   PubMed Web of Science ®Google Scholar
• Al-Tassan N, Chmiel NH, Maynard J et al. Inherited variants of MYH associated with somatic G:C --> T:A mutation in colorectal tumors. Nat. Genet.30(2), 227–332 (2002).
   PubMed Web of Science ®Google Scholar
• Peltomaki P, Aaltonene L, Sistonen P et al. Genetic mapping of a locus predisponing to human colorectal cancer. Science260(5109), 810–812 (1993).
   PubMed Web of Science ®Google Scholar
• Quehenberger F, Vasen HFA, van Houwelingen HC. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J. Med. Genet.42(6), 491–496 (2005).
   PubMed Web of Science ®Google Scholar
• Vasen HFA, Stormorken A, Menko FH et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J. Clin. Oncol.19, 4074–4080 (2001).
   PubMed Web of Science ®Google Scholar
• Aarnio M, Mecklin JP, Aaltonen LA et al. Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer64, 430–433 (1995).
   PubMed Web of Science ®Google Scholar
• Aarnio M, Sankila R, Pukkala E et al. Cancer risk in mutation carriers of DNA mismatch-repair genes. Int. J. Cancer81, 214–218 (1999).
   PubMed Web of Science ®Google Scholar
• Parc Y, Boisson C, Thomas G et al. Cancer risk in 348 French MSH2 or MLH1 gene carriers. J. Med. Genet.40, 208–213 (2003).
   PubMed Web of Science ®Google Scholar
• Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam. Cancer1, 57–60 (2001).
   PubMedGoogle Scholar
• Hendriks YM, de Jong AE, Morreau H et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J. Clin.56(4), 213–225 (2006).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Potter JD. Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks of bowel cancer and other biliary and intestinal diseases? Am. J. Epidemiol.118(5), 620–627 (1983).
   PubMed Web of Science ®Google Scholar
• Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J. Natl Cancer Inst.67(1), 57–60 (1981).
   PubMedGoogle Scholar
• Grodstein F, Martinez ME, Platz EA et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann. Intern. Med.128(9), 705–712 (1998).
   PubMed Web of Science ®Google Scholar
• Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med.106(5), 574–582 (1999).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Wactawaski-Wende J, Ritenbaugh C et al. Estrogens plus progestin and colorectal cancer in postmenopausal women. N. Engl. J. Med.350(10), 991–1004 (2004).
   PubMed Web of Science ®Google Scholar
• Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control14(10), 979–984 (2003).
   PubMed Web of Science ®Google Scholar
• Slattery ML, Potter JD, Curtin K et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res.61(1), 126–130 (2001).
   PubMed Web of Science ®Google Scholar
• Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst.90(11), 814–823 (1998).
   PubMed Web of Science ®Google Scholar
• Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocr. Rev.26(3), 465–478 (2005).
   PubMed Web of Science ®Google Scholar
• Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW. ERβ has nongenomic action in caveolae. Mol. Endocrinol.16(5), 938–946 (2002).
   PubMed Web of Science ®Google Scholar
• Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol.18(12), 2854–2865 (2004).
   PubMed Web of Science ®Google Scholar
• Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett.238(1), 1–14 (2006).
   PubMed Web of Science ®Google Scholar
• Nilsson S, Mäkelä S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev.81(4), 1535–1565 (2001).
   PubMed Web of Science ®Google Scholar
• Pettersson K, Gustafsson JA. Role of estrogen receptor β in estrogen action. Ann. Rev. Physiol.63, 165–192 (2001).
   PubMed Web of Science ®Google Scholar
• Couse JF, Korach KS. Estrogen receptor null mice. What have we learned and where will they lead us? Endocr. Rev.20(3), 358–417 (1999).
   PubMed Web of Science ®Google Scholar
• Xie LQ, Yu JP, Luo HS. Expression of estrogen receptor β in human colorectal cancer. World J. Gastroenterol.10(2), 214–217 (2004).
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Kominea A, Vandoros G et al. Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur. J. Cancer39(9), 1251–1258 (2003).
   PubMed Web of Science ®Google Scholar
• Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of estrogen receptor β in colon cancer and its association with Duke’s staging. Oncol. Rep.14(1), 17–21 (2005).
   PubMed Web of Science ®Google Scholar
• Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem. Biophys. Res. Commun.261(2), 521–527 (1999).
   PubMed Web of Science ®Google Scholar
• Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor β mRNA in colon cancer cells: growth effects of estrogen and genistein. Biochem. Biophys. Res. Commun.270(2), 425–431 (2000).
   PubMed Web of Science ®Google Scholar
• Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res.61(2), 632–640 (2001).
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor β mediated system. Cancer Lett.161(1), 63–71 (2000).
   PubMed Web of Science ®Google Scholar
• Nojima D, Li LC, Dharia A et al. CpG hypermethylation of the promoter region inactivates the estrogen receptor-β gene in patients with prostate carcinoma. Cancer92(8), 2076–2083 (2001).
   PubMed Web of Science ®Google Scholar
• Zhao C, Lam EW, Sunters A et al. Expression of estrogen receptor β isoform in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene22(48), 7600–7606 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang X, Leung YK, Ho SM. AP-2 regulates the transcription of estrogen receptor (ER)-β by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene26(52), 7346–7354 (2007).
   PubMed Web of Science ®Google Scholar
• Liu MM, Albanese C, Anderson CM et al. Opposing action of estrogen receptors alpha and β on cyclin D1 gene expression. J. Biol. Chem.277(27), 24353–24360 (2002).
   PubMed Web of Science ®Google Scholar
• Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene19(43), 4970–4978 (2000).
   PubMed Web of Science ®Google Scholar
• Weihua Z, Makela S, Andersson LC et al. A role for estrogen receptor β in the regulation of growth of the ventral prostate. Proc. Natl Acad. Sci. USA98(11), 6330–6335 (2001).
   PubMed Web of Science ®Google Scholar
• Paech K, Webb P, Kuiper GG et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science277(5331), 1508–1510 (1997).
   PubMed Web of Science ®Google Scholar
• Martineti V, Picariello L, Tognarini I et al. ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr. Relat. Cancer12(2), 455–469 (2005).
   PubMed Web of Science ®Google Scholar
• Wada-Hiraike O, Imamov O, Hiraike H et al. Role of estrogen receptor β in colonic epithelium. Proc. Natl Acad. Sci. USA103(8), 2959–2964 (2006).
   PubMed Web of Science ®Google Scholar
• Narayan S, Rajakumar G, Prouix H, Singh P. Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA. Gastroenterology103(6), 1823–1832 (1992).
   PubMed Web of Science ®Google Scholar
• Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anti Cancer Res.14(3A), 1037–1041 (1994).
   PubMed Web of Science ®Google Scholar
• Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor β in colon cancer cells. Biochem. Biophys. Res. Commun.261(2), 521–527 (1999).
   PubMed Web of Science ®Google Scholar
• Weyant MJ, Carothers AM, Mahmoud NN et al. Reciprocal expression of ERα and ERβ is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res.61(6), 2547–2551 (2001).
   PubMed Web of Science ®Google Scholar
• Hsu HH, Cheng SF, Wu CC et al. Apoptotic effects of over-expressed estrogen receptor-β on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. China J. Physiol.49(2), 110–116 (2006).
   PubMed Web of Science ®Google Scholar
• Lee H, Jiang F, Wang Q et al. MEKK1 activation of human estrogen receptor β and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol.14(11), 1882–1896 (2000).
   PubMed Web of Science ®Google Scholar
• Driggers PH, Segars JH, Rubino DM. The protooncoprotein Brx activates estrogen receptor β by a p38 mitogen-activated protein kinase pathway. J. Biol. Chem.276(50), 46792–46797 (2001).
   PubMed Web of Science ®Google Scholar
• Chen SL, Chang YJ, Wu YH, Lin KH. Mitogenactivated protein kinases potentiate thyroid hormone receptor transcriptional activity by stabilizing its protein. Endocrinology144(4), 1407–1419 (2003).
   PubMed Web of Science ®Google Scholar
• Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol. Cell. Biol.22(16), 5835–5845 (2002).
   PubMed Web of Science ®Google Scholar
• Wilpart M, Mainguet P, Maskens A, Roberfroid M. Mutagenicity of 1,2-dimethylhydrazine towards Salmonella typhimurium, co-mutagenic effect of secondary biliary acids. Carcinogenesis4(1), 45–48 (1983).
   PubMed Web of Science ®Google Scholar
• Allende HD, Ona FV, Davis HT. Gallbladder disease: risk factor for colorectal carcinoma? J. Clin. Gastroenterol.6(1), 51–55 (1984).
   PubMed Web of Science ®Google Scholar
• McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J. Natl Cancer Inst.65(6), 1201–1207 (1980).
   PubMed Web of Science ®Google Scholar
• Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut51(2), 191–194 (2002).
   PubMed Web of Science ®Google Scholar
• Powell DR, Suwanichkul A, Cubbage ML, DePaolis LA, Snuggs MB, Lee PD. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J. Biol. Chem.266(28), 18868–18876 (1991).
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J. Nutr.131(Suppl. 11), S3109–S3120 (2001).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA282(7), 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Black DM et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone33(3), 293–300 (2003).
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R et al. Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J. Bone Miner. Res.20(9), 1514–1524 (2005).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat.65(2), 125–134 (2001).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA281(23), 2189–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst.96(23), 1751–1761 (2004).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA295(23), 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA; Multiple Outcomes of Raloxifene Evaluation (MORE) Trial. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA287(2), 216–220 (2002).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J. Bone Miner. Res.19(8), 1270–1275 (2004).
   PubMed Web of Science ®Google Scholar
• Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation – breast cancer as a secondary end point: implications for prevention. Ann. NY Acad. Sci.949, 134–142 (2001).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P et al. Raloxifene Use for The Heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med.355(2), 125–137 (2006).
   PubMed Web of Science ®Google Scholar
• Picariello L, Fiorelli G, Martineti V et al. Growth response of colon cancer cell lines to selective estrogen receptor modulators. Anti Cancer Res.23(3B), 2419–2424 (2003).
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Lemmen JG, Carlsson B et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology139(10), 4252–4263 (1998).
   PubMed Web of Science ®Google Scholar
• Herold C, Ganslmayer M, Ocker M et al. Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int. J. Oncol.23(3), 751–756 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh JME, Cheung AM, Yang D, Litwack S, Grady D. Raloxifene and colorectal cancer. J. Womens Health (Larchmt).14(4), 299–305 (2005).
   PubMed Web of Science ®Google Scholar
• Yin F, Shi YQ, Chen CP et al. Expression of cDNA fragment encoding MGr1-Ag1 detected by MDR related antibody MGr1 in gastric cancer. Shi Jie Hua Ren Xiao Hua Za Zhi11, 18–21 (2003).
   Google Scholar
• Uchiyama-Kokubu N, Watanabe T. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs12(9), 769–779 (2001).
   PubMed Web of Science ®Google Scholar
• Wang BL, Zhai HY, Chen BY et al. Clinical relationship between MDR1 gene and gallbladder cancer. Hepatobiliary Pancreat. Dis. Int.3(2), 296–299 (2004).
   PubMedGoogle Scholar
• Lorke DE, Kruger M, Buchert R, Bohuslavizki KH, Clausen M, Schumacher U. In vitro and in vivo tracer characteristics of an established multidrug-resistant human colon cancer cell line. J. Nucl. Med.42(4), 646–654 (2001).
   PubMed Web of Science ®Google Scholar
• Shen LZ, Hua YB, Yu XM et al. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo. World J. Gastroenterol.11(7), 1060–1064 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton G, Cosentini EP, Teleky B et al. The multidrug-resistance modifiers verapamil, cyclosporine A and tamoxifen induce an intracellular acidification in colon carcinoma cell lines In vitro. Anti Cancer Res.13(6A), 2059–2063 (1993).
   PubMed Web of Science ®Google Scholar